Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

DENTSPLY SIRONA (NASDAQ:XRAY - Get Rating) had its target price reduced by investment analysts at The Goldman Sachs Group from $42.00 to $41.00 in a research note issued on Thursday, The Fly reports. The Goldman Sachs Group's target price would suggest a potential upside of 13.48% from the stock's previous close.

A number of other equities analysts also recently commented on XRAY. HC Wainwright decreased their target price on DENTSPLY SIRONA from $58.00 to $48.00 and set a "hold" rating for the company in a research note on Friday, April 22nd. StockNews.com raised DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research report on Thursday. Bank of America downgraded shares of DENTSPLY SIRONA from a "buy" rating to a "neutral" rating and reduced their price target for the company from $66.00 to $49.00 in a report on Tuesday, April 19th. Barrington Research dropped their price objective on shares of DENTSPLY SIRONA from $53.00 to $51.00 in a report on Wednesday, May 11th. Finally, UBS Group upgraded shares of DENTSPLY SIRONA from a "neutral" rating to a "buy" rating and cut their price objective for the company from $58.00 to $47.00 in a research report on Wednesday, June 1st. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $48.11.DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $36.13 on Thursday. The company has a current ratio of 1.45, a quick ratio of 1.03 and a debt-to-equity ratio of 0.38. The firm has a market cap of $7.78 billion, a price-to-earnings ratio of 21.38 and a beta of 0.94. DENTSPLY SIRONA has a 52 week low of $33.78 and a 52 week high of $66.98. The stock has a 50 day moving average of $37.10 and a 200-day moving average of $45.57.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Rating) last released its earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.02. DENTSPLY SIRONA had a net margin of 8.81% and a return on equity of 11.63%. The firm had revenue of $9.67 billion during the quarter, compared to analyst estimates of $982.05 million. During the same quarter in the previous year, the firm earned $0.72 earnings per share. The firm's revenue for the quarter was up 841.1% compared to the same quarter last year. As a group, analysts forecast that DENTSPLY SIRONA will post 2.42 EPS for the current year. Insider Buying and Selling

In other news, Director Eric Brandt sold 6,900 shares of the business's stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $39.71, for a total value of $273,999.00. Following the sale, the director now owns 35,155 shares of the company's stock, valued at approximately $1,396,005.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.76% of the stock is owned by corporate insiders. Hedge Funds Weigh In On DENTSPLY SIRONA

Several large investors have recently made changes to their positions in XRAY. SOA Wealth Advisors LLC. lifted its stake in DENTSPLY SIRONA by 26,666.7% during the first quarter. SOA Wealth Advisors LLC. now owns 803 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 800 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in shares of DENTSPLY SIRONA by 33.8% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,224 shares of the medical instruments supplier's stock valued at $43,000 after acquiring an additional 309 shares during the last quarter. National Bank of Canada FI bought a new stake in shares of DENTSPLY SIRONA during the 4th quarter worth $55,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new stake in shares of DENTSPLY SIRONA during the first quarter worth $79,000. Finally, Covestor Ltd acquired a new stake in shares of DENTSPLY SIRONA during the fourth quarter worth $90,000. Institutional investors own 94.79% of the company's stock. About DENTSPLY SIRONA (Get Rating)

DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.Further ReadingGet a free copy of the StockNews.com research report on DENTSPLY SIRONA (XRAY)Are General Electric's Downgrades A Warning Sign Or A Buying Opportunity?Get These 3 Juicy Dividend Yields While They Last Exxon Mobil Leads The Oil Sector: Have Both Peaked?These 3 Mega Caps are Bear Market BuysHow Low Can DocuSign Stock Go?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider DENTSPLY SIRONA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.

While DENTSPLY SIRONA currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

In this episode, Kate chats with regular guest Rob Isbitts, who, as always, debunks some traditional investing ideas, such as “buy the dip” and only going long while the market is in rally mode.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.